Dr. Mohammed Abdo Hashem is currently working as Senior Lecturer (Assistant Professor) with the department of Mechanical Engineering at Faculty of Engineering in University of Malaya starting from April 2021-Onwards.  He has a quite long experience in teaching courses in the fields of Mechanical and Mechatronics Engineering for more than 8 years. Besides that, he was working as engineer in several industrial companies for more 3 years. In 2015, He was appointed as a senior lecturer and leader of control, software and automation teaching & research groups, in the Faculty of Manufacturing Engineering- Universiti Malaysia Pahang, where he led many research and teaching activities during the period of appointment between 2015 and 2021.  In the research, a total of four patents have been granted to his novel research and products, namely; laser simulator approach for path planning, intelligent spanner and the autonomous road marks painting system version 1&2; with furthermore publishing more than 60 papers in high indexed ISI journals, Scopus, chapters and conferences. He recieved more than 12 grants as leader from MOHE (1FRGS and 1 PRGS) and Universiti Malaysia Pahang (8 RDU grants).  His research interests include, but are not limited to the following areas: Autonomous Mobile Robot Navigation, Artificial Intelligence, Robot Path Planning, SLAM, Industrial Robotics, Mobile Manipulators, Sensors Fusion, Mechatronics Systems, Automation and IR.4, Intelligent Active Force Control, Signal and Image Processing. He is currently working, in his research group, on developing a novel AI algorithm, called laser simulator logic, that helps to avoid the drawbacks of current fuzzy logic type 1 and 2, especially in the noisy environments of industrial systems.     

Zamri obtained his BSc in Chemistry and MSc in pharmacology from the University of Malaya and later PhD in Clinical Pharmacology from the University of London (UK) in 2007. Soon after completed his doctorate degree, he joined the Department of pharmacology, University of Malaya as a senior lecturer and currently serves as a Professor in the Department of Pharmacology and also Head of Universiti Malaya Research Centre for Biopharmaceuticals and Advanced Therapeutics (UBAT). He was recently awarded a Fellow by the British Pharmacological Society (FBPhS). His scope of research includes bioavailability and pharmacokinetic studies in human and animal models, drug delivery systems such as PEG-PLGA nanoparticles for systemic drug delivery, and semi solid formulations for transdermal and topical preparation.  Apart from human clinical trials and preclinical studies in animals, his research also covers the development of humanized mice model for cancers and cell based therapy for cancers. His laboratory also provides services and research in adulterated pharmaceutical products, xenobiotic studies on certain chemicals such as endocrine disruptors in food products, human bodies, etc. using GCMS, HPLC, LCMSMS, etc. Apart from his research activities, he also actively provided consultation to local pharmaceutical companies to conduct testing on pharmaceutical formulations especially for bioequivalence studies, comparative dissolution, etc. His bioequivalence laboratory has conducted more than 40 bioequivalence studies for generic drug formulations and also conducted drug analysis in biological and pharmaceutical formulations.   

Dr. Nurshamimi was awarded a Malaysia-Imperial Doctoral Programme to study HPV regulation at the Department of Virology, St. Mary’s Campus, Imperial College London, upon graduating with an M.Med.Sc from the University of Malaya in 2008. She joined the Department of Molecular Medicine as a Senior Lecturer in 2014 and was promoted to Associate Professor in 2021. She was a three-time travel award winner for attending HKU-Pasteur workshops at the University of Hong Kong. She also received travel awards from the International Papillomavirus Society in 2017 for the HPV conference in South Africa and a travel award from the EMBL Advanced Training Centre Corporate Partnership Program Fellowship in 2015 for the EMBO Conference in Heidelberg, Germany. She is also a member of the European Association for Cancer Research (EACR) and the European Society for Virology. In 2020, she won the Bill & Melinda Gates Foundation Young Investigator Award for her work on the Chikungunya virus, and in 2022, she received a travel award from Keystone Symposia, Global Health Travel Award, USA. In 2024, she was selected by Cold Spring Harbor Laboratory, USA, to present her work entitled "Morindone from Morinda citrifolia—A promising agent targeting DNA replication and key mutations in colorectal cancer" at their conference 'Mechanisms and Models of Cancer'. Dr. Nurshamimi also holds several patents in the field of anti-aging and colorectal cancer. Her current research is geared toward phase 1 clinical trials for diabetic foot ulcer treatment and investigating potential leads for colorectal cancer targets. She is an Ambassador for Bentham Science Publisher, one of the most renowned ISI publishers in the world. Currently, she is a principal investigator for research projects on colorectal cancer, Zika and dengue viruses, anti-aging, and diabetic foot ulcers.